

**EFFECTS OF IMPAIRED GLUCOSE METABOLISM, AGING AND
METEOROLOGICAL FACTORS ON HEMORHEOLOGICAL
PARAMETERS AND PLATELET AGGREGATION**

Ph.D. thesis

Author: Katalin Koltai, MD

Tutor: Kálmán Tóth, MD, DSc

1st Department of Medicine, School of Medicine
University of Pécs
Hungary
2008

CONTENTS

1. Introduction	3
2. Aims	13
3. The effect of blood glucose levels on hemorheological parameters, platelet activation and aggregation in oral glucose tolerance tests	14
3.1 Background	14
3.2 Patients and methods	15
3.3. Results	18
3.4 Discussion	22
3.5 Conclusion	24
4. Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin and thienopyridine treated patients	26
4.1 Background	26
4.2 Materials and methods	27
4.3 Results	28
4.4 Discussion	33
4.5 Conclusions	35
5. Investigation of seasonal differences in hemorheological parameters and platelet aggregability and their association with meteorological factors	37
5.1 Patients and methods	37
5.2 Results	38
5.3 Discussion	44
5.4 Conclusion	49
6. List of abbreviations	50
7. References	51

8. Publications of the author	67
Acknowledgements	70

1. Introduction

Hemorheology is the science of blood flow that deals with the deformation and flow properties of blood and its elements under mechanical forces. Blood is a non-Newtonian fluid, a suspension of cells, chylomicrons, carbohydrates, proteins, electrolytes in an aqueous medium.

Numerous studies have investigated the effects of aging on different hemorheological parameters. Age-associated changes have been described among others in the rheological properties of erythrocytes, plasma proteins, fibrinogen level, fibrin degradation products and blood viscosity. It is suspected that the increased incidence of cardio-and cerebrovascular diseases in the elderly may partially be due to age-related hemorheological alterations, i.e. hyperviscosity due to elevated fibrinogen level and altered erythrocyte properties may negatively influence hemodynamics and impair tissue oxygenisation. Fibrinogen is a high-molecular-weight (340.000) glycoprotein, a main determinant of plasma viscosity, and it also plays a role in erythrocyte and platelet aggregation as well as in the activation of the coagulation system. A significant rise was found in plasma viscosity and fibrinogen associated with aging in several studies. Bauer et al. [1] found higher concentrations of fibrinopeptide A in elderly subjects that refers to a more frequent activation of prothrombin and also to a more rapid production of fibrinogen in older subjects. In a study by Avellone et al. on 600 individuals a significant increase in plasma viscosity and fibrinogen was found due to aging [2]. In a study by Tarallo et al. fibrinogen was found to be higher in children than in adults (age between 20-30 years). However, in adults older than 30 years a gradual increase in fibrinogen levels was observed in both sexes. Ott et al. studied a group of asymptomatic cerebrovascular patients and found that older patients (mean age 59 years) exhibited significantly higher values of fibrinogen than younger individuals (mean age: 48 years) [3].

The Bezafibrate Infarction Prevention study [4] also showed a significant increase in fibrinogen levels both in men and women. In this study, correlations were found for plasma viscosity and fibrinogen ($r=0.81$) and triglycerides ($r=0.42$). Hager et al. reported a significant increase with age for erythrocyte sedimentation rate, plasma cholesterol and triglycerides and a significant decrease in albumin in a group of 156 subjects aged 23-96 years [5]. De Simone et al. [6] found a correlation between age and plasma viscosity and globulin fraction in 127 normotensive subjects. A study by Sharp et al. [7] on 3571 elderly Japanese American men showed a significant correlation between age, elevated fibrinogen and chances of having coronary heart disease. A study by Banerjee et al. [8] found that fibrinogen was the best single discriminator for myocardial infarction in an elderly population. A rise of 1 g/l increased the probability of death by 2-fold in the next 6 years. Feher et al. found a weak but statistically significant correlation between selected hemorheological parameters (plasma viscosity, fibrinogen) and aging in 6234 cardio-and cerebrovascular patients, however, in a subgroup of old males whole blood viscosity and its main determinants were negatively correlated with advancing age. Also in a subgroup of 623 patients with matching parameters (risk factors, previous diseases, and medication) no significant association was found between hemorheological parameters and aging and the observed increase in the examined parameters in the whole population were contributed to a higher number of concomittant diseases in the elderly.

Platelet aggregation basically influences coagulation and blood flow dynamics. A study of 116 hypertensive and 142 normotensive individuals showed an increase with age in platelet aggregation [9]. ADP-induced platelet aggregation showed a more pronounced increase compared to epinephrine induced platelet aggregation in this study.

In a study of 18 smokers and 34 nonsmokers collagen-induced platelet aggregation was found to increase significantly with age in the nonsmoker group [10].

Diabetes mellitus is a clinical term denoting a group of metabolic impairments which affect glucose utilization and lead to hyperglycemia. The importance of diabetes is reflected by the fact that the worldwide prevalence of the disease is projected to double to 300 million by 2025. Type 1 diabetes is characterized by the complete absence of insulin, while type 2 diabetes is characterized by hyperinsulinemia and insulin resistance which precedes the development of hyperglycemia. The latter form of diabetes accounts for at least 90% of diabetic cases worldwide and it is associated with modern lifestyle characterized by abundant nutrient supply and reduced physical activity. As vascular disease represents the main etiology for death, and accounts for a great percent of morbidity in diabetic patients, poorly controlled diabetes is considered to be a vascular disease. Hyperglycemia may influence hemorheological parameters through enhanced advanced glycation end product (AGE) formation. Reducing sugars may react non-enzimatically with the amino groups in proteins or lipids that ultimately leads to the formation of stable covalent adducts, the AGEs. AGEs can bind to biological membranes in a nonspecific manner, but they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with RAGE (receptor for AGE), a cellular surface receptor that binds AGE-modified proteins with high affinity. Several other receptors and cell surface molecules that are capable of binding AGE-modified proteins have been identified recently. The consequence of AGE-RAGE interaction is the generation of reactive oxygen species (ROS), partially caused by the activation of NADPH oxidase. AGE-RAGE interaction induces the expression of vascular endothelial growth factor (VEGF) in endothelial cells. AGEs also inhibit prostacyclin production and stimulate plasminogen activator inhibitor-1 (PAI-1) synthesis by endothelial cells. AGEs thus stimulate the growth of microvascular endothelial cells, leading to angiogenesis on one hand and to a pro-thrombotic state on the other hand [11-14].

Obesity is both a cause and a consequence of type-2 diabetes mellitus. The adipose tissue synthesizes and releases numerous bioactive substances, several of which are known to have an effect on blood rheology. PAI-1 and interleukin-6, important regulators of plasma fibrinogen level, are also produced in significant amounts by adipocytes. Low-grade inflammation is present in adiposity as reflected by elevated levels of C-reactive protein, interleukin-6 and tumor necrosis factor- α in obese individuals. The low-grade, chronic inflammatory state may contribute to insulin resistance and endothelial dysfunction. Adipose tissue also releases leptin, a cytokine that circulates at high concentrations in the plasma of obese, insulin resistant patients. This hormone has been recently shown to stimulate proliferation and migration of myocytes in the vessel wall, and thus been suggested to be a possible pathogenic factor for atherosclerosis. Positive correlations have been reported between leptin and both plasma viscosity and RBC partial disaggregation threshold measured by laser backscattering [15].

Accelerated atherosclerosis in type-2 diabetic patients is multifactorial and includes very complex interactions, including hyperglycemia, hyperinsulinemia, hyperproinsulinemia, dyslipidemia, oxidative stress, accelerated aging, platelet hyperreactivity as well as alterations in coagulation and fibrinolysis and changes in hemorheological parameters. The initial lesion of atherosclerosis is manifested in changes of endothelial cell function. Endothelial dysfunction has been shown to be manifested in patients with type-2 diabetes as well as in type-1 diabetic patients early in the course of the disease, especially when microalbuminuria is present. Moreover, endothelial dysfunction has been shown to be present in insulin resistant patients with impaired glucose tolerance (IGT) and in individuals with former gestational diabetes [16]. There is a growing body of evidence showing that poly(ADP) ribose polymerase (PARP) activation has an important role in the pathophysiology of endothelial dysfunction in diabetes. In animal models, destruction of pancreatic islet cells with

streptozotocin leads to PARP activation and endothelial dysfunction. Studies on wild-type and PARP deficient mice showed that elevated blood glucose levels represented a very strong stimulus for PARP activation. These studies led to the conclusion that PARP activation due to hyperglycemia is influenced by the genesis of superoxide species; O₂ free radicals may be produced in endothelial cells exposed to hyperglycemia.

Hemorheological parameters

Glycemic control seems to be a major factor for determining the hemorheological consequences of diabetes. Type-1 diabetic patients with poor glycemic control exhibit increased plasma and whole blood viscosity when compared to normoglycemic individuals; blood viscosity is also negatively correlated with insulin sensitivity. Treatment of insulin resistance by exercise training specifically improves plasma viscosity due to the close association between plasma viscosity and insulin sensitivity. Positive associations have also been found between parameters of glycemic control (HbA1C, fructoseamine), fibrinogen levels and red blood cell aggregation; fibrinogen levels are also closely correlated to insulin resistance. A single hyperglycemic spike increases red blood cell aggregation in both type-1 and type-2 diabetic patients and alters fibrinogen concentration and activity in type-1 diabetic patients.

Several studies have reported that insulin improves hemorheological abnormalities in diabetes, and when studied in vitro, incubation of red cells obtained from diabetic patients with insulin resulted in improved cellular deformability as measured by micropore filtration. Interestingly, this observation could not be reproduced when utilizing washed red blood cells. These ex vivo results suggest a direct effect of insulin on red cell membrane fluidity, although beneficial hemorheological effects related to insulin treatment in vivo may be indirectly mediated by metabolic improvements. Nevertheless, it now seems that insulin affects red cell

rheology via direct effects on the membrane, including alterations of the lipid membrane bilayer composition and microviscosity and changes in membrane Na/K ATPase function. It is interesting to note that supra-physiological levels of insulin can have adverse effects on red cell deformability, with very high in vitro levels decreasing red blood cell deformability.

Both type-1 and type-2 diabetes are associated with diabetic thrombocytopathy, a condition related to increased platelet adhesiveness and aggregability. Enhanced platelet aggregation is present in diabetes early in the course of the disease, well before the development of diabetic vascular lesions. Several biochemical abnormalities play a role in diabetic platelet hyperreactivity:

1) membrane fluidity is reduced due to changes in the lipid composition of the membrane or glycation of membrane proteins;

2) increased intracellular Ca^{2+} levels and decreased magnesium concentrations reduce membrane fluidity and increase platelet adhesiveness;

3) platelets from diabetic individuals produce less NO and prostacyclin, agents which normally promote endothelium-mediated vasodilation and inhibit platelet-endothelium interactions;

4) increased platelet arachidonic acid metabolism leads to enhanced TXA₂ production, a possible underlying cause for platelet hyperreactivity;

5) platelets from diabetic subjects contain reduced levels of antioxidant molecules which might also contribute to their hyperaggregability.

The binding of fibrinogen to the GP IIb-IIIa receptor is increased in diabetic patients, and they also have a higher ratio of platelets expressing activation-dependent adhesion molecules such as activated GP IIb-IIIa, lysosomal Gp53, thrombospondin and P-selectin; plasma fibrinogen levels are also increased in both types of diabetes. Platelets may interact with

glycosylated low density lipoproteins, von Willebrand factor or immune complexes, and platelet turnover may be shortened in diabetes, thereby contributing to the observation that antiplatelet agents such as aspirin and clopidogrel have a diminished effect in these patients. Chronically poor metabolic control is associated with increased platelet activation and aggregation. Hyperglycemia has been described to result in enhanced platelet aggregation, with reduced sensitivity to aspirin observed in type-2 diabetic patients having poor metabolic control. Soluble P-selectin is a widely accepted marker for platelet activation: elevated plasma levels have been proved to be significantly associated with diabetes mellitus [17-19].

Polymorphonuclear leukocytes derived from diabetic patients were found to be more rigid as measured by filtration techniques, suggesting an activated stage of these cells. Leukocytes are larger and much more rigid than erythrocytes, thus they can strongly influence microvascular blood flow. Moreover, polymorphonuclear leukocytes (PMN), the largest fraction of leukocytes, are capable of causing microvascular damage by the release of proteases and toxic oxygen radicals. Comparing PMN of normoglycemic and diabetic patients, the rigidity of leukocytes obtained from individuals with diabetes is significantly elevated both in their basal stage and following their activation with the bacterial polypeptide fMLP. Diabetic and hypertensive individuals have less deformable PMN than patients with diabetes and normal blood pressure [20-22].

Chronobiology is the „scientific discipline concerned with the definition, mechanisms, and significance of the so-called time structure of life forms” [23]. While homeostasis presumes a relatively constant internal state, chronobiology presumes „human bioprocesses and functions exhibit predictable variability in time, biological rhythms, at every level of organization” [23].

Variations in the annual per capita death rates in different countries are well documented. Less well known are seasonal variations in death rates with the highest levels occurring

during the colder winter months as it has been described in many countries. This phenomenon is referred to as excess winter mortality. A seasonal variation in the incidence of MI, cardiac death, and stroke is consistently described. CVD-related deaths account for the majority of excess winter deaths (up to 70% in some countries) [24,25], while about half of the remaining are due to increases in respiratory diseases. Correlation between seasons and attacks of coronary thrombosis was first noted in 1926 [26]. Seasonal variations in cardiovascular mortality have been documented in both northern and southern hemispheres [27-30], while seasonal changes are absent in equatorial regions [30]. The mechanisms underlying this variation, which holds true in both cold and milder climates, are not fully understood. Seasonal deaths from MI may partially be due to endogenous physiological rhythms in cardiovascular risk factors. Large annual blood pressure amplitude has been observed with a peak in winter and a trough in the summer [31,32]. Circannual rhythms have been described in parameters as fibrinogen, hematocrit, platelet count [33] hormones [34,35], serum lipids, and glucose [36,37]. Total cholesterol, HDL-C and LDL-C showed seasonal alterations in many studies with a peak in winter and a trough in the summer months [38]. Several findings may explain this phenomenon. Higher intake of total fat in winter was shown in a Danish study [39]. Seasonal variation in intake of fat, beta-carotene and vitamins A, C and E was found in a study by Woodhouse et al [40]. Beta-carotene and vitamin A intakes peaked in autumn and winter while vitamin C and E intakes reached their highest level in summer. Glycemic parameters as hemoglobin A_{1C} values showed a seasonal rhythm in diabetic patients [41]. Fluctuations in glucose and insulin sensitivity were demonstrated in several studies, with higher levels in the fall or winter in most studies [42-44]. Microvascular disease related complications also follow a seasonal pattern in diabetes. Initiation of dialysis for patients with end-stage renal disease is more common in January and least common in August [45]. Data concerning a possible seasonal variation in endothelial function is controversial. Widlansky et

al. observed in the Framingham Offspring Cohort that brachial artery flow-mediated dilatation was lowest in winter [46]. Conduit artery endothelial function was most strongly related to season. On the other hand, Klein-Wiegel et al. found no seasonal variation in flow-mediated dilatation of the brachial artery either in women with primary Raynaud's phenomenon or in healthy controls [47].

In developed countries, death rates for cardiovascular disease (CVD) have decreased nearly 60 % from their peaks in the 1960s and 1970s. Hungary, with one of the highest mortality rates in Europe has shown a delayed start from the mid-1990s in this decline [48-50]. Exogenous factors such as climate, diet, physical activity levels, heating and air conditioning may directly or indirectly influence endogenous rhythms such as blood pressure, coagulation factors or platelet count, rendering the body more vulnerable to cardiovascular events. MI mortality has been shown to increase both with low and high temperatures, therefore climatic trends and changes to indoor environments may influence its seasonal variation [51,52]. Increased use of central heating and air conditioning alleviates temperature stress in winter and summer respectively and may interfere with seasonal variation of cardiovascular risk factors. Seretakis et al. [53] reported a sharp decline in seasonal variation for coronary deaths in the US from 1937-1970, followed by a reversal of this trend in the period between 1970-1991. The authors proposed that the increase in the second time frame of their study resulted from the increased use of air conditioning, which blunted the effects of heat waves on coronary mortality, thus the increase in seasonal variation was due to a decrease in summer deaths.

Several other studies found a negative correlation between MI mortality and mean monthly temperatures [54,55]. A Northern Irish study of MI mortality between 1979-1990 found that death rate for both sexes for MI decreased by 2.2 % for each 1 °C [56]. The same

study examined the effect of hours of sunshine per month and found no significant relationship between the level of sunshine and mortality.

While improvements in lifestyle, diet, housing and medical care may have contributed to decreased mortality rates, seasonal fluctuations remain a significant problem.

2. Aims

1. Rheological factors and increased platelet aggregation are convincingly implicated in the development of micro- and macrovascular diseases associated with diabetes mellitus. The presented examination has been designed to describe the effects of a standard oral glucose load on hemorheological parameters, platelet activation and aggregation in patients with normal and pathologic glucose tolerance.

2. In the second part of my work I aimed to investigate the association between the effectiveness of the most widely used antiplatelet therapies (100 and 300-325 mg acetylsalicylic acid (ASA), 75 mg clopidogrel, 500 mg ticlopidine and the combination of 100 mg aspirin and 75 mg clopidogrel), fibrinogen levels and aging.

3. In the third part of my work I aimed to investigate whether hemorheological parameters and platelet aggregability show seasonal differences in a population with established vascular disease. A possible association with certain meteorological factors as ambient temperature, daily amount of sunshine hours, relative humidity and simultaneous changes in air pressure was also investigated.

3. The effect of blood glucose levels on hemorheological parameters, platelet activation and aggregation in oral glucose tolerance tests

3.1. Background

Cardio- and cerebrovascular diseases and their complications are the leading cause of morbidity and mortality in the world. Hemorheological parameters were proved to be independent risk factors [57-67], however, many „classic” risk factors have an influence on blood rheology [68]. Rheological factors are also convincingly implicated in the development of diabetic microvascular diseases [69]. Several studies have proved that a chronic poor metabolic control is associated both with pathologic alterations of hemorheological parameters [11,13,70-72] and with increased platelet activation and aggregation [73,74]. Reduced sensitivity to aspirin observed in type 2 diabetic patients has been ascribed to poor metabolic control [75]. Several in vitro studies have been performed to clarify the effect of acute changes in glucose concentration on hemorheological parameters and platelet aggregation [76,77]. At the same time much less data are available on how glucose consumption influences these factors in vivo, and the precise time course of events has not yet been fully elucidated. Hyperglycemia has been described to result in enhanced platelet aggregation, however, very little data can be found whether there is a relationship between platelet activation and aggregation and blood glucose levels within the normoglycemic range. Soluble P-selectin (sP-selectin) is taken as a plasma marker of platelet activation by many investigators [78,79]. sP-selectin levels have been proved to be significantly associated with diabetes mellitus [80]. The present study has been designed to clear whether or not acute changes in blood glucose levels have an immediate effect on hemorheological parameters, platelet activation and aggregation in oral glucose tolerance tests (OGTT).

3.2. Patients and methods

Study population

Oral glucose tolerance test was performed in 30 patients (12 males, 18 females, mean age: 58 ± 10 years) suspected to have diabetes mellitus. OGTT was in all cases medically indicated (high cardiovascular risk, previously measured fasting glucose levels were between 6.0-7.0 mmol/l). The study was approved by the regional ethics committee. All participants agreed to participate and signed an informed consent. Exclusion criteria were any inflammatory or malignant conditions, surgical or invasive procedure, or infarction within 6 months before the recruitment. Mean body mass index (BMI) was 31.5 ± 5 kg/m².

OGTT

After an overnight fast, fasting glucose levels were measured, then patients were loaded with 75 g glucose. Blood samples were taken 1, 2, and 3 hours after the oral glucose load. Based on the 2-hour result of the tests, patients were divided into a normal glucose tolerance (NGT) group (glucose levels below 7.8 mmol/l at the 2-hour sampling) and an impaired glucose tolerance/diabetes mellitus (IGT/DM) group, where 2-hour glucose values were above the normal limits.

Hemorheological measurements

Hematocrit, erythrocyte aggregation, red blood cell filtration and P-selectin measurements were performed at room temperature (22 ± 1 °C), whole blood and plasma viscosity and platelet aggregation measurements at 37 °C within two hours after venepuncture.

Hematocrit:

Venous blood collected into lithium-heparin coated Vacutainer tubes was centrifugated in hematocrit capillaries at 12000 rpm for five minutes in a microhematocrit centrifuge (Hemofuge, Heraeus Instr., Germany).

RBC aggregation:

RBC aggregation measurements were carried out from venous blood samples collected into lithium-heparin coated Vacutainer tubes. RBC aggregation was measured in Myrenne aggregometer (MA-1 Aggregometer, Myrenne GmbH, Germany) applying the light transmission method of Schmid-Schonbein et al. [81,82]. The aggregometer has two modes of operation: M and M1. For both modes blood sample (30 μ l) is first sheared at 600 s^{-1} to disperse all pre-existing aggregates, then shear rate decreases rapidly to zero (M0 mode) or low shear (M1 mode). The extent of aggregation is characterized by the aggregation index (AI_M , AI_{M1}), calculated from the surface area below the light intensity curve in a 10 s measurement period.

Plasma and whole blood viscosity:

Plasma and whole blood viscosity were determined in Hevimet 40 capillary viscosimeter (Hemorex Ltd., Hungary) from venous blood samples collected into lithium-heparin coated Vacutainer tubes. Plasma was obtained by centrifugating samples at 1500 g for ten minutes. 1.0-1.0 ml plasma or whole blood was injected into the capillary tube of the viscosimeter. In this device the flow of the fluid is detected optoelectronically along the capillary tube and a flow curve is drawn. Shear rate and shear stress are calculated from this curve, viscosity values are determined as a function of these parameters according to Casson's principle. For the presentation of our results, apparent whole blood viscosity values calculated at 90 s^{-1} shear rate are given.

RBC filtration:

RBC filterability, a variable referring to cell deformability was measured in a Carat FT-1 Filtrometer (Carat Diagnostics Ltd., Hungary) using the St George's technique. In this apparatus RBC suspension flows through a Nucleopore filter with 5 μm pores. Filtration rate is calculated from the data measured at four pairs of light sources and detectors. The device is interfaced to a computer, which automatically analyses sequential flow rates and thus distinguishes the cell transit time (relative cell transit time) and the pore clogging rate. In our experiments, filtrating pressure was set to 4 cm of water. All measurements were repeated three times for each sample.

Platelet aggregation:

Platelet-rich plasma (PRP) was separated by centrifugation at 150g for 10 minutes. After carefully removing PRP, the remaining samples were further centrifugated at 2500g for 10 minutes to obtain platelet-poor plasma (PPP). Platelet aggregation was measured by Carat TX-4 optical platelet aggregometer (Carat Diagnostics Ltd., Hungary) at 37 °C within two hours after vein puncture. 10, 5 and 2,5 μM ADP, 2 and 1 $\mu\text{g/ml}$ collagen, 10 and 5 μM epinephrine inducers were used.

sP-selectin:

Determination of the level of sP-selectin was performed by using a sandwich ELISA procedure according to manufacturer's instructions (Bender MedSystems, Austria). sP-selectin was determined from platelet poor plasma prepared as described above.

Statistical analysis

Patients were divided into two groups based on the result of OGTT. The IGT/DM group consisted of 14, either diabetic or IGT patients, the NGT group consisted of 16 non-diabetic patients. All data in the text and tables are expressed as means \pm standard error of the

mean (S.E.M.). Student's t test for paired data was used to calculate differences between baseline results and measurements at other time-points. Pearson's linear correlation coefficients were calculated between variables. Student's t test for unpaired data was used to determine differences between the IGT/DM and the NGT group in the case of hematocrit, whole blood and plasma viscosity, red blood cell aggregation and filtration and P-selectin measurements. The minimum value used to establish statistical significance was $p < 0.05$.

3.3. Results

Diagnosis of diabetes mellitus was confirmed if the 2-hour glucose level was more than 11.1 mmol/l, IGT was diagnosed if the 2-hour result was between 7.8 and 11.1 mmol/l. Blood glucose levels in the different groups are represented in Table 1. BMI was significantly higher in the IGT/DM group ($p < 0.05$). Red blood cell aggregation showed a significant elevation in the course of time in all groups, however, in IGT/DM patients the elevation was more expressed and could already be observed in the 2nd hour of the examination (Table 1).

Both the M0 and M1 indices correlated significantly with BMI in the IGT/DM group ($p < 0.01$), but no significant association could be found between these parameters in patients with normal glucose tolerance (Table 2).

			Fasting	1 hour	2 hours	3 hours
Glucose (mmol/l)	NGT (n=16)		5.29 ± 0.49 ↑*	9.20 ± 1.82‡ ↑	6.67 ± 1.30‡ ↑	4.20 ± 1.24† ↑
	IGT/DM (n=14)		6.07 ± 1.25 ↓	12.58 ± 2.12‡ ↓	11.96 ± 3.44‡ ↓	7.43 ± 3.51 ↓
Hematocrit (%)	NGT (n=16)		43.1 ± 3.2	42.9 ± 3.2	42.9 ± 3.9	42.6 ± 3.6*
	IGT/DM (n=14)		44.2 ± 3.9	43.7 ± 3.3	43.0 ± 4.7*	42.8 ± 3.1*
Red blood cell aggregation	M0	NGT (n=16)	13.87 ± 2.93	13.47 ± 2.83	14.62 ± 2.36	14.85 ± 2.35
		IGT/DM (n=14)	13.99 ± 4.52	15.16 ± 3.86	16.38 ± 3.54*	16.77 ± 4.34†
	M1	NGT (n=16)	25.51 ± 3.57	25.75 ± 3.66	26.22 ± 3.44 ↑*	27.01 ± 3.68† ↑*
		IGT/DM (n=14)	27.15 ± 5.71	27.94 ± 5.20	29.96 ± 5.23† ↓	30.81 ± 4.07‡ ↓
Plasma viscosity (mPas)	NGT (n=13)		1.30 ± 0.09	1.29 ± 0.06	1.28 ± 0.14	1.28 ± 0.17
	IGT/DM (n=13)		1.33 ± 0.12	1.25 ± 0.13†	1.28 ± 0.07†	1.25 ± 0.09†
Whole blood viscosity (mPas)	NGT (n=13)		4.45 ± 0.57	4.41 ± 0.52 ↑*	4.24 ± 0.75	4.30 ± 0.61
	IGT/DM (n=13)		4.62 ± 0.53	4.79 ± 0.59 ↓	4.59 ± 0.70	4.54 ± 0.48
Red blood cell filtration	NGT (n=13)		6.9 ± 0.49	6.88 ± 0.53	7.11 ± 0.58	7.03 ± 0.55
	IGT/DM (n=12)		6.9 ± 0.49	7.01 ± 0.50	7.24 ± 0.46	7.15 ± 0.65
sP-selectin (ng/ml)	NGT (n=13)		6.4 ± 2.9	4.5 ± 2.7 ↑*	4.9 ± 2.4	6.5 ± 2.36
	IGT/DM (n=12)		9.6 ± 9.9	14.9 ± 20.8 ↓	12.1 ± 14.4	12.3 ± 12.6

*p<0.05 †p<0.01 ‡p<0.001

Table 1. Blood glucose levels, hemorheological parameters compared to fasting values in oral glucose tolerance tests (values are represented as mean ± SEM)

		BMI
NGT	M0 (n=16)	r=0.0957 NS
	M1 (n=16)	r=0.3581 NS
IGT/DM	M0 (n=14)	r=0.7740 p<0.01
	M1 (n=14)	r=0.7407 p<0.01

Table 2. Correlation coefficient and its significance between M and M1 indices and BMI in NGT and IGT/DM patients

M0 and M1 indices did not correlate significantly with coinstantaneous blood glucose levels. The M1 index was significantly higher in the IGT/DM group than in the NGT group at the 2- and 3-hour samplings (p<0.05).

Plasma viscosity in the IGT/DM group showed significant decrease in all samplings compared to baseline values, while no statistically significant changes could be observed in the NGT group (Table 1).

Whole blood viscosity was significantly higher in the IGT/DM group at the one-hour measurements (p<0.05), but not at the other tested time-points. However, it did not change significantly in the course of time in either groups.

Hematocrit decreased statistically significantly in the IGT/DM group in the 2nd hour, while in the NGT group only in the 3rd hour and to a lesser extent (Table 1).

Red blood cell filtration did not show significant changes at any time points in this study, and no significant difference was found between the two groups either (Table 1).

Platelet aggregation showed statistically significant decrease at the 1-hour measurements compared to baseline values both in the non-diabetic and in the diabetic/IGT group in the case

of higher ADP concentrations, but no significant changes could be observed with other inducers (Table 3).

		Fasting	1 hour	2 hours	3 hours
NGT	ADP 10µM	72.5 ± 6.9	67.9 ± 14.2	71.1 ± 9.8	67.3 ± 13.0
	ADP 5 µM	69.1 ± 9.1	64.7 ± 13.5 *	67.8 ± 8.8	68.6 ± 11.3
	ADP 2.5 µM	60.4 ± 14.1	60.9 ± 16.3	57.9 ± 18.6	56.5 ± 21.0
	Coll 2 µg/ml	56.8 ± 23.8	54.1 ± 23.8	58.2 ± 24.2	57.9 ± 24.1
	Coll 1 µg/ml	47.9 ± 23.8	49.0 ± 26.6	43.1 ± 26.4	45.3 ± 27.9
	Epi 10 µM	53.9 ± 23.9	45.7 ± 24.3	53.0 ± 28.5	49.2 ± 28.1
	Epi 5 µM	55.1 ± 21.1	45.4 ± 24.4	45.6 ± 28.5	47.5 ± 24.0
	Spont. aggr.	4.0 ± 3.6	9.2 ± 16.5	5.4 ± 5.0	4.5 ± 6.5
IGT/DM	ADP 10 µM	75.5 ± 7.7	69.8 ± 9.7 †	71.8 ± 9.2	72.3 ± 11.7
	ADP 5 µM	66.9 ± 12.1	69.2 ± 9.7	69.5 ± 10.5	69.8 ± 13.6
	ADP 2.5 µM	59.7 ± 16.1	59.2 ± 15.7	56.7 ± 23.3	58.9 ± 20.7
	Coll 2 µg/ml	64.9 ± 12.2	64.7 ± 14.6	61.9 ± 20.3	55.9 ± 25.3
	Coll 1 µg/ml	50.1 ± 22.5	49.5 ± 26.8	54.4 ± 27.7	52.4 ± 26.5
	Epi 10 µM	61.0 ± 21.2	54.9 ± 26.6	58.1 ± 27.6	56.1 ± 35.5
	Epi 5 µM	47.6 ± 26.0	52.7 ± 29.0	57.1 ± 27.6	56.1 ± 32.3
	Spont. aggr.	14.4 ± 23.1	9.6 ± 17.8	10.2 ± 19.2	8.5 ± 16.7

*p<0.05 †p<0.01

Table 3. Platelet aggregation measured in optical aggregometer during OGTT in the different groups (values are represented as mean ± SEM)

Difference between platelet aggregation in IGT/DM patients and the nondiabetic group could not be tested because of the lack of homogenous antiplatelet therapy. sP-selectin concentrations did not show significant changes in either examined groups in the course of time. However, IGT/DM patients showed significantly higher sP-selectin concentrations at the 1-hour measurements (p<0.05) than the NGT group (Table 1).

3.4. Discussion

Long-term effects of poor metabolic control have been proved to result in erythrocyte hyperaggregability [72] and hyperviscosity [11,71]. However, much less information could be found on the immediate effects of changes in blood glucose levels on hemorheology and platelet aggregation in vivo, and results are often controversial. Although whole blood viscosity did not change significantly in this study, plasma viscosity decreased significantly in IGT/DM patients, while it showed no changes in non-diabetics. These results are partially in accordance with the results of Khodabandehlou et al. [83], who reported a significant decrease in both plasma- and whole blood viscosities in type-1 diabetic patients during a hyperglycemic spike. However, in their study hematocrit levels remained unchanged, while our investigation showed a clinically minor, although statistically significant decrease in hematocrit levels that was more pronounced in the IGT/DM group. These results implicate that increased blood osmolality due to elevated blood glucose levels may lead to a fluid influx from the interstitial space into the circulation.

Previous studies have already shown association between BMI and erythrocyte aggregation [16,84]. Interestingly, this study shows a strong correlation between BMI and erythrocyte aggregation in IGT/DM patients, but no association between these parameters in patients with normal glucose tolerance. Elevated M1 values seen in the IGT/DM group might be associated with enhanced levels of fibrinogen and CRP, known to be present in impaired glucose tolerance and diabetes mellitus. Our unpublished data of 106 type-2 diabetic, vascular patients show significant association between CRP and BMI ($p < 0.01$); fibrinogen was found to be significantly associated to BMI ($p < 0.05$), while the M1 aggregation index was related to both CRP ($n=191$, $p < 0.01$) and BMI ($p < 0.05$). A recent study found body fat to be an important predictor of plasma fibrinogen level [85]. These relationships between fibrinogen, CRP and BMI/body fat may support the theory that erythrocyte aggregation is related to BMI through

low-grade inflammation. Data on the correlation between blood glucose levels and erythrocyte aggregation are controversial in the literature. A recent study found that erythrocyte aggregation elevated with the increase of glucose concentration [70]. Other investigators reported significant decrease in erythrocyte aggregation during short-term hyperglycemia in type-1 diabetic patients [83]. Our results showed a significant increase in erythrocyte aggregation in both M0 and M1 modes from the 2nd hour sampling on in the IGT/DM group. Red blood cell aggregation in NGT patients also elevated in the course of time, however, to a lesser extent than in patients with abnormal glucose tolerance. Interestingly, the increase in erythrocyte aggregation did not follow immediately the elevation of glucose levels. The correlation between glucose levels and the M1 aggregation index tended to be stronger -although never significant- when M1 levels were compared to glucose levels measured an hour earlier. These results may suggest that the increase in erythrocyte aggregation following glucose consumption is due to the elevation of insulin levels [86], and a marked elevation of erythrocyte aggregation during OGTT might be a sign of hyperinsulinemia. This would also explain the differences between our findings and the decreased erythrocyte aggregation seen in type-1 diabetic patients lacking insulin during hyperglycemia [75]. Nevertheless, a further study is needed to prove this hypothesis.

Poor metabolic control on the long term is known to affect red blood cell filterability [87]. In this study, however, red blood cell filterability did not change significantly after the oral glucose load, although a tendency to increase –most recognisable at 2 hours after glucose consumption – was present.

Very few data are available in the literature on the immediate effects of glucose consumption on soluble P-selectin levels. In this study, results are controversial, as two patients showed a very high rise in sP-selectin levels in the course of time, which could not be explained with any of the investigated parameters, while the great majority of the participants did not show

any significant changes in sP-selectin levels. A further study with more functional and morphological parameters of platelets, and with more participants with homogenous medication could possibly clarify this question.

It has not been cleared whether or not, and how glucose consumption influences platelet activation and aggregation in the course of time. In a recent in vitro study platelet activation proved to be increased after exposure to high concentrations of both glucose and mannitol, proving the role of increased osmolarity in enhanced platelet aggregation and activation [77]. Our in vivo results, however, showed no significant changes in platelet aggregation at the tested time points compared to baseline values with most tested inducer concentrations. Platelet aggregation induced by higher concentrations of ADP showed significant alterations at the 1 hour sampling, but these results were inconsequent inasmuch only one tested concentration resulted in a significant change in both groups. Results obtained in this investigation are also contradictory to data seen in the in vitro studies. Our hypothesis to explain the lack of increase in platelet aggregation in this study is an interference with the circadian pattern of platelet aggregability, which is highest in the morning hours [88]. It is also possible that blood glucose levels seen in IGT/DM patients in this study were not elevated enough to increase platelet aggregation in vivo. A further study with separate subgroups of type-2 diabetic and IGT patients with uniform antiplatelet medication would be needed to clarify this question.

3.5. Conclusion

Glucose consumption influences hematocrit, plasma viscosity and red blood cell aggregation, however, a direct association between actual glucose levels and these parameters could not be shown in this study. Red blood cell aggregation is associated with BMI, possibly through

low-grade inflammation known to be present in obesity. Erythrocyte aggregation after glucose consumption might be influenced by changing insulin levels in the course of time. Changes in plasma viscosity and hematocrit levels might be caused by an influx from the interstitial space into the circulation due to elevated osmolality.

4. Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin and thienopyridine treated patients

4.1. Background

Increasing life expectancy has led to a growing population of elderly patients with ischemic heart diseases taking antiplatelet medication. Antiplatelet therapy has an established role in the primary and secondary prevention of cardiovascular diseases based on the results of large-scale clinical trials and meta-analyses that have demonstrated a significant reduction of risk of acute myocardial infarction, cardiovascular death and stroke. Aspirin is effective in reducing the risk of serious vascular events by 25 % [89]. However, several *in vitro* and clinical studies have shown interindividual differences in ASA responsiveness [89]. Neither is the effect of thienopyridines uniform in all patients. Current available data show that 4-30% of patients treated with clopidogrel fail to display adequate antiplatelet response [90]. Previous studies have reported a link between advancing age and prothrombotic changes [91,92]. Measurement of blood tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) levels suggest that thrombolytic activity is also reduced with aging [93,94]. The relation of platelet reactivity to aging has also been studied with platelet function tests in a few studies, however, findings were contradicting [93,95,96]. In spite of these facts, only few data can be found on the efficiency of antiplatelet regimens in the elderly. In our present study we aim to describe differences between different age groups in *in vitro* platelet aggregation and fibrinogen levels in a large number of vascular patients treated with different antiplatelet regimens.

4.2. Materials and methods

Patients

Between 2001 and 2005, platelet aggregation was checked in 5026 patients with clinical evidence of vascular diseases receiving antiplatelet therapy in our laboratory. Platelet aggregation tests were performed to analyze whether the chosen antiplatelet medication was effective. Age, sex, and antiplatelet agent taken were recorded in all patients. Patients were under antiplatelet therapy for at least 4 weeks at the time of testing. 3389 patients received aspirin therapy (100, 300 or 325 mg per day, mean age: 63 ± 11 years, 1661 males, 1728 females). 970 patients took 75 mg clopidogrel (mean age: 64 ± 10 , 539 males, 431 females). 362 patients took 500 mg ticlopidine (mean age: 63 ± 10 , 212 males, 150 females). We also investigated 305 patients who received a combination of 100 mg ASA and 75 mg clopidogrel (mean age: 62 ± 10 , 201 males, 104 females.) Patient compliance to antiplatelet treatment was assessed by interview. Fibrinogen level was measured in 3243 patients by the method of Clauss.

Platelet aggregation tests

Blood samples anticoagulated with sodium citrate were taken between 8 a.m. and 10 a.m. from each patient after an overnight fast. Platelet-rich plasma (PRP) was separated by centrifugation at 150g for 10 minutes. After carefully removing PRP, the remaining samples were further centrifugated at 2500g for 10 minutes to obtain platelet-poor plasma (PPP). Platelet aggregation was measured by Carat TX-4 optical platelet aggregometer (Carat Diagnostics Ltd., Hungary) at 37 °C within two hours after vein puncture according to Born's method. Platelet aggregation was evaluated considering the maximal percentage of platelet aggregation in response to 5 and 10 μ M ADP, 2 μ g/ml collagen, and 10 μ M epinephrine inducers.

Statistical analysis

Continuous variables are presented as means \pm SD. The Kolmogorov-Smirnov and Shapiro-Wilk tests were used to investigate normal distribution of data. Subjects were divided by age decade. Age groups containing more than 5 individuals were evaluated. In the case of normal distribution Student's t test for unpaired data was used to compare age groups. In the case of non-normal distribution the robust Welch test [97] was used. Pearson's linear correlation coefficients were calculated between variables in the case of normally distributed data, Spearman's correlation was assessed in the case of non-normal distribution. A p value <0.05 was considered statistically significant. Analyses were performed using SPSS 11.0 (SPSS Inc. Chicago, Ill.) and Microsoft Excel.

4.3. Results

In patients treated with 100 and 300-325 mg ASA platelet aggregation increased significantly across age decades, in the case of the former dosage with all but the collagen inducer, while in the latter with all used inducers. Patients aged ≥ 80 years exhibited significantly higher aggregation indices than individuals aged less than 40 years ($p < 0.001$) (Table 4-5).

Age (years)	<40 (n=62)	40-49 (n=263)	50-59 (n=673)	60-69 (n=824)	70-79 (n=683)	≥80 (n=124)	p value*
ADP 5 μM	58.6 (14.5)	61.8 (14.0)	62.2 (13.8)	63.2 (12.2)	64.1 (11.2)	66.6 (12.7)	<0.001
ADP 10 μM	63.6 (11.9)	66.6 (12.1)	66.6 (11.7)	67.6 (10.7)	68.2 (10.4)	68.4 (10.6)	<0.001
Collagen 2 μg/ml	47.4 (28.2)	47.2 (26.1)	45.8 (26.0)	46.2 (23.8)	45.1 (22.6)	48.0 (21.5)	0.122
Epinephrine 10 μM	45.9 (28.5)	45.8 (28.3)	45.0 (27.2)	48.6 (25.1)	49.3 (23.4)	55.8 (24.1)	<0.001

*Table 4. Platelet aggregation induced with different stimulants in patients treated with 100 mg ASA stratified by age
Data are presented as means (SDs)
Assessed linear trend across age

Age (years)	<40 (n=21)	40-49 (n=73)	50-59 (n=213)	60-69 (n=254)	70-79 (n=171)	≥80 (n=28)	p value*
ADP 5 μM	53.9 (11.0)	61.0(11.6)	63.2 (12.1)	63.0 (10.7)	64.7 (10.3)	66.2(10.2)	<0.001
ADP 10 μM	61.8 (9.4)	65.1 (10.9)	68.1(9.9)	68.2 (9.9)	68.5 (9.1)	70.3 (7.5)	0.005
Collagen 2 μg/ml	27.8 (17.4)	33.7 (23.2)	37.4 (23.6)	37.5 (21.6)	42.4 (20.0)	48.1(18.7)	<0.001
Epinephrine 10 μM	24.8 (15.9)	30.0 (18.9)	38.6 (23.8)	40.0 (20.8)	45.2 (22.1)	54.8(21.3)	<0.001

*Table 5. Platelet aggregation induced with different stimulants in patients treated with 300-325 mg ASA stratified by age
Data are presented as means (SDs)
Assessed linear trend across age

At the same time we found no association between platelet aggregation and aging either in patients treated with 75 mg clopidogrel or with 500 mg ticlopidine (Table 6-7).

Age (years)	<40 (n=19)	40-49 (n=64)	50-59 (n=246)	60-69 (n=344)	70-79 (n=259)	≥80 (n=38)	p value*
ADP 5 μM	45.4 (24.8)	49.8 (23.3)	50.2 (21.4)	52.5 (20.3)	53.7 (19.5)	47.8 (21.1)	0.198
ADP 10 μM	46.4 (25.4)	53.9 (20.0)	55.1 (20.8)	56.0 (19.0)	57.7 (17.8)	54.3 (22.5)	0.470
Collagen 2 μg/ml	68.5 (19.6)	62.2 (23.1)	63.9 (22.0)	65.9 (18.2)	63.1 (21.1)	61.3 (21.2)	0.366
Epinephrine 10 μM	68.3 (32.8)	75.5 (22.8)	73.4 (22.4)	77.1 (19.6)	75.7 (19.4)	73.6 (16.9)	0.309

Table 6. Platelet aggregation induced with different stimulants in patients treated with 75 mg clopidogrel stratified by age

Data are presented as means (SDs)

**Assessed linear trend across age*

Age (years)	40-49 (n=28)	50-59 (n=108)	60-69 (n=118)	70-79 (n=94)	≥80 (n=13)	p value*
ADP 5 μM	47.9 (23.0)	45.2 (19.9)	42.3 (18.8)	44.6 (17.7)	45.5 (24.9)	0.709
ADP 10 μM	50.2 (22.5)	48.9 (22.4)	45.7 (18.8)	48.6 (18.3)	51.5 (21.7)	0.611
Collagen 2 μg/ml	73.2 (11.4)	65.0 (18.1)	60.7 (21.3)	62.0 (19.6)	58.0 (27.2)	0.420
Epinephrine 10 μM	80.1 (17.8)	77.4 (20.3)	74.2 (20.9)	76.7 (18.6)	71.7 (29.6)	0.503

Table 7. Platelet aggregation induced with different stimulants in patients treated with 500 mg ticlopidine by age decades

Data are presented as means (SDs)

**Assessed linear trend across age*

However, in the case of combination therapy with 100 mg aspirin and 75 mg clopidogrel the association between platelet aggregation and age was similar to that seen in patients treated only with ASA ($p < 0.001$) (Table 8).

Age (years)	40-49 (n=37)	50-59 (n=88)	60-69 (n=93)	70-79 (n=79)	p value*
ADP 5 μ M	40.2 (16.6)	45.9 (14.9)	47.6 (13.0)	52.4 (15.5)	0.001
ADP 10 μ M	47.0 (17.6)	52.0 (15.7)	53.0 (14.1)	56.9 (15.3)	0.001
Collagen 2 μ g/ml	28.4 (23.7)	32.7 (25.1)	33.0 (21.3)	33.0 (23.9)	0.566
Epinephrine 10 μ M	36.7 (26.2)	41.7 (23.5)	48.3 (21.9)	52.9 (23.4)	0.001

Table 8. Platelet aggregation induced with different stimulants in patients treated with a combination of 75 mg clopidogrel and 100 mg ASA by age decades

Data are presented as means (SDs)


**Assessed linear trend across age*

Fibrinogen levels increased significantly across age decades in ASA treated patients, and significant difference was found between the oldest age group and patients aged less than 40 years ($p < 0.001$). In patients treated with thienopyridines no association was found between fibrinogen levels and aging. Neither was any difference found between different age groups in patients taking ASA–clopidogrel combination therapy (Table 9).

Age (years)	<40	40-49	50-59	60-69	70-79	≥80	p value*
ASA 100 mg n=1873	3.26 (0.89)	3.46 (0.96)	3.50 (0.81)	3.61 (0.83)	3.70 (0.84)	3.84 (0.85)	<0.001
ASA 300-325 mg n=580	3.33 (0.69)	3.51 (0.63)	3.67 (0.79)	3.66 (0.79)	3.63 (0.78)	3.71 (0.68)	<0.001
ticlopidine 500 mg n=292	-	3.23 (0.64)	3.26 (0.90)	3.20 (0.79)	3.07 (0.63)	3.06 (0.93)	0.099
clopidogrel 75 mg n=345	-	3.50 (0.77)	3.62 (0.92)	3.53 (0.80)	3.47 (0.80)	3.58 (0.51)	0.533
ASA 100 mg + clopidogrel 75 mg n=153	-	3.64 (0.97)	3.31 (0.90)	3.61 (0.86)	3.65 (0.71)	-	0.059

*Table 9. Fibrinogen levels in the case of different antiplatelet regimens by age decades
Data are presented as means (SDs)
Assessed linear trend across age

Fibrinogen levels were significantly lower in the case of clopidogrel and ticlopidine treatment than in patients treated with ASA ($p < 0.001$), and ticlopidine treated patients had significantly lower fibrinogen levels than patients treated with clopidogrel ($p < 0.001$). Individuals treated with a combination of ASA and clopidogrel exhibited fibrinogen levels which did not differ significantly from results detected in either ASA or clopidogrel monotherapy, but that were significantly higher than in the case of ticlopidine treatment (Figure 1).



*Figure 1. Fibrinogen levels in patients treated with different antiplatelet agents
Data are represented as means \pm SDs*

4.4. Discussion

According to clinical investigations, antiplatelet therapies are not uniformly effective in all patients. There is a huge body of data available showing that 5-45% of patients treated with aspirin do not achieve the inhibitory response anticipated on the basis of different laboratory measurements of platelet activation and aggregation [98-103]. In vitro resistance to aspirin has been found to be significantly associated with an increase of arterial thrombotic events [104,105]. Resistance to thienopyridines both in vitro and in vivo has also been described [90,106]. Up to 5-11% of clopidogrel-treated patients were found to be non-responders, while 9-26% were semi-responders [107]. 8.7% of ticlopidine treated patients were found to be non-responders [108]. Very few data could be found on the association

between platelet aggregability, the efficiency of antiplatelet regimens and aging [109,110], in spite of the fact that elderly patients are known to be at an increased risk of cardio- and cerebrovascular events [89]. In a study of 3230 individuals without evidence of cardiovascular disease Tofler et al. found that fibrinogen, von Willebrand factor and measures of impaired fibrinolytic potential as plasminogen activator inhibitor and tissue plasminogen activator antigens were significantly associated with advancing age indicative of a prothrombotic state [92]. Significantly reduced spontaneous thrombolytic activity has also been proved in older patients [93,111]. Similarly to these results an age associated increase was found in fibrinogen level in ASA treated patients in our present study. Fibrinogen has been identified as an important risk factor of cardio- and cerebrovascular events which plays an important role in platelet aggregation [91,112,113]. Age associated increase in fibrinogen level may play a crucial role in increased platelet aggregation in elderly patients found in this study. Independence of fibrinogen levels of age in both clopidogrel and ticlopidine treated patients might be contributed to the beneficial effect of these drugs on fibrinogen levels [114] also seen in our study. Platelet aggregability may be negatively influenced by several factors in the elderly. Elder patients tend to have more co-morbidities and take more drugs that raise the potential of drug interactions. NSAIDs have been shown to interact with aspirin's antiplatelet effect. A higher incidence of chronic heart failure may contribute to the decrease in aspirin's antiplatelet effect in the older population, as the prevalence of aspirin resistance in this population has been shown to be more than double than in patients with stable general vascular disease [111]. A higher prevalence of other chronic diseases as diabetes, hypertension and dyslipidemia may further increase the propensity for increased platelet activation and aspirin resistance [115]. An other possible cause of increased *in vitro* platelet aggregation in older people may be due to long-lasting aspirin treatment, as this has been

shown to be associated with a progressive reduction in platelet sensitivity to this drug [108,116,117].

Aspirin is a potent inhibitor of collagen and epinephrine induced platelet aggregation in *in vitro* tests, but has only a moderate effect on ADP induced platelet aggregation. Therefore, interindividual differences in ASA sensitivity lead to a wider distribution of values in the case of collagen and epinephrine inducers, hence the larger standard deviation in these cases. The present study has a number of limitations. This was a non-randomized, observational study. Several factors that may further explain the differences observed in platelet aggregation and fibrinogen levels in the different age and drug groups (plasma lipid levels, concomitant medication, case history) were not investigated. The type and dosage of antiplatelet agent(s) taken were documented based on medical records and interview. However, compliance was not checked with direct methods. Further tests exist to investigate platelet aggregability (urinary thromboxane measurements, arachidonic acid induced aggregation etc.) that were not used in this study and might lead to different results. Data of patients less than 40 and more than 80 years could not be evaluated in the case of certain regimens because of low number of cases. Prospective, randomized further examinations are needed to confirm our results in a multivariate analysis.

4.5. Conclusions

Effective antiplatelet therapy is of particular importance in older patients being at increased risk of vascular events. Age-related increase in platelet aggregability may contribute to higher risk of cardio- and cerebrovascular diseases in this age group. Therefore, effective antiplatelet therapy in the elderly should be more carefully checked and perhaps individually determined.

Elevation of fibrinogen levels that occurs with aging may contribute to the observed increase in *in vitro* platelet aggregation in ASA treated patients.

5. Investigation of seasonal differences in hemorheological parameters and platelet aggregability and their association with meteorological factors

5. 1. Patients and methods

Patients

Between 2001 and 2005, platelet aggregation was checked in our laboratory in 2693 patients (1417 males, 1276 females, age: 62.9 ± 11.2 years) with clinical evidence of vascular disease receiving a daily dose of 100 mg aspirin. Platelet aggregation tests were performed to analyze whether the chosen antiplatelet medication was effective. Patients were under antiplatelet therapy for at least 4 weeks at the time of testing. In a subgroup of 1873 patients fibrinogen level was measured by the method of Clauss. In 1260 patients plasma and whole blood viscosity and hematocrit were also tested. In a third subgroup of 724 patients we assessed erythrocyte aggregation. Patients are residents of an area within 40 km-s from the local station of the Hungarian Meteorological Service.

Materials and methods

Hematocrit and erythrocyte aggregation, whole blood and plasma viscosity were assessed as described previously (page 16-17). Platelet aggregation measurements were performed as described on page 27 using 5 and 10 μM ADP, 2 $\mu\text{g/ml}$ collagen and 10 μM epinephrine inducers.

External temperature at 8 a.m., daily maximal and minimal temperatures, air pressure at 8 a.m. and 10 a.m., relative humidity and daily amount of precipitation were assessed in the local station of the Hungarian Meteorological Service. Daily temperature variation (difference between daily minimal and maximal temperatures) was assessed. Difference between air

pressure at 8 and 10 a.m. (Δp) was calculated as an indicator of meteorological front activity at the time-point of sampling.

Statistical analysis

Continuous variables are presented as means \pm SD. The Kolmogorov-Smirnov test was used to investigate normal distribution of data. Data were divided into 12 groups according to the months of the year based on the time-point of the examination. To compare means of data in different months we used one-way ANOVA. Peak and trough monthly values were compared by Student's t-test or the Mann-Whitney U test. Pearson's linear correlation coefficients were calculated between variables in the case of normally distributed data, Spearman's correlation was assessed in the case of non-normal distribution. A p value <0.05 was considered statistically significant. Analyses were performed using SPSS 11.0 (SPSS Inc. Chicago, Ill.) and Microsoft Excel.

5.2. Results

Similarly to other investigators we found significantly higher fibrinogen levels in the winter than in the summer with a peak in December and a trough in July ($p < 0.01$) (Figure 2).




Figure 2. Monthly alterations in plasma fibrinogen levels

Both the M0 and M1 indices proved to be significantly higher in the winter than in the summer months ($p < 0.0001$) with a peak in December (M0) and January (M1) and a trough in July and June, respectively (Figure 3-4).




Figure 3. Seasonal changes in M0 index




Figure 4. Seasonal changes in M1 index




Figure 5. Monthly changes in whole blood viscosity




Figure 6. Monthly changes in plasma viscosity

Differences between winter-and summer results of whole blood viscosity measurements were not significant. Plasma viscosity showed significantly higher values in the hottest months than in the winter (Figure 5-6).

Epinephrine-induced platelet aggregation was highest in April and May, while its minimum was in August and September ($p<0.001$) (Figure 7).




Figure 7. Seasonal changes in epinephrine induced platelet aggregation

Significant negative correlation was found between external temperature measured at 8 a.m. as well as daily minimal and maximal temperatures and M0 and M1 indices ($p<0.001$) (Figure 9). Plasma viscosity showed a positive correlation with daily minimal temperatures ($p<0.001$). A weak, but statistically significant correlation was found between platelet aggregation induced with ADP 10 and all examined temperature parameters ($p<0.01$), however, no significant association was found with either the smaller dose of ADP inducer or with the other applied inducers. Fibrinogen and hematocrit exhibited a weak negative association with ambient temperature ($p<0.05$). Neither of the examined hemorheological and platelet aggregation parameters were associated with daily temperature variability or with changes in

air pressure between 8 and 10 a.m. Air pressure measured at 8, 9, and 10 a.m. showed a significant positive correlation with M0 ($p < 0.001$) and M1 ($p < 0.01$) indices. Plasma- and whole blood viscosity were negatively correlated to air pressure ($p < 0.01$ and $p < 0.05$, respectively). Daily precipitation and humidity at 8 and 10 a.m. were not associated with any examined hemorheological or platelet aggregation parameters.




Figure 8: Monthly variation of hematocrit




Figure 9: Association between ambient temperature and red blood cell aggregation

5.3. Discussion

Higher cardio- and cerebrovascular mortality in the winter in areas of the world where ambient temperatures show huge seasonal differences has been observed in large-scale analyses [24,27]. Exogenous factors such as climate, diet, activity levels, heating and air conditioning, upper respiratory infections have been described to influence directly or indirectly the homeostasis and have an effect on hemorheological and hematological rhythms [118,119]. Some authors have suggested that an acute phase response triggered by upper respiratory tract infections was responsible for the higher incidence of acute coronary syndromes during the winter months [36]. However, data on seasonal variation of major acute-phase reactant CRP levels are contradicting. In two studies, seasonal variation of CRP was investigated on an intraindividual basis. Woodhouse et al. reported higher CRP concentrations in winter with a peak in March [36]. Crawford et al. found a significant seasonal variation of CRP with a peak in late February, but detected no seasonal rhythm in white cell count or IL-6 [120]. No evidence for seasonal variation of CRP was found in large populations in a study by Fröhlich et al [29] and an investigation by Stout et al. in elderly people [121]. This data in a way contradicts results showing a seasonal pattern in a variety of acute-phase proteins as PAI-1, plasminogen or fibrinogen [38], as also seen in the present study for the latter. However, in contrast to CRP, coagulation proteins are not exclusively related to the acute phase response.

Fibrinogen is an independent risk factor for cardiovascular diseases [122]. Fibrinogen levels showed a high-amplitude yearly variation in a study by Maes et al. [33]. Seasonal differences in fibrinogen levels have been described to be higher in older age groups [121,123,124]. In contrast to previous investigators, differences between winter- and summer fibrinogen levels were relatively small in our study. This might be the consequence of a younger mean age of

patients in our study. Also, patients in our investigation were homogeneously treated with a 100 mg daily dose of aspirin that might influence seasonal patterns in fibrinogen levels. We found a weak negative correlation between fibrinogen levels and both daily minimal and maximal temperature values as well as temperature measured at 8 a.m. This finding is in concordance with the results of Stout et al., they found that core body temperature showed a statistically significant seasonal variation and a peak corresponding with those for ambient temperatures, fibrinogen and MPV [30]. Maes and De Meyer reported seasonal rhythms in MPV and fibrinogen together with their association with climatic data [33]. They propose that the seasonal rhythms observed in immune and hematologic variables may be entrained by the seasonal rhythms in ambient temperature [58].

A strong seasonal variation was found for plasma viscosity with a maximum in January and a minimum in July in a study by Fröhlich et al. [38]. Significant, however, less pronounced seasonal differences for whole blood viscosity were also found by the same group. Otto et al. found a significant reduction in native blood viscosity in their study of 14 healthy, middle aged individuals over 6 months. However, they found no alterations concerning hematocrit, plasma viscosity and fibrinogen concentration [125]. Opposite to these results, we found a statistically significant but clinically minor difference between winter and summer values with a peak in July and a trough in January in plasma viscosity values that might be indicative of inadequate fluid intake in the summer months in the examined population. Ambient temperature was found to be negatively correlated to plasma viscosity and erythrocyte deformability of *ex vivo* samples in a study by Cinar et al. [126]. However, in the present study neither plasma nor whole blood viscosity were associated with ambient temperature. Surprisingly, we observed a weak negative correlation between whole blood and plasma viscosity and air pressure measured at 8 and 10 a.m. We suspect that ambient air

pressure might have a minor influence on the result of capillary viscosimetry, however, this theory needs further investigation.

Hematocrit has been found to show a „group-seasonal” effect in the population in general. However, the results of studies from different geographical areas indicate a climatic effect: a study from Iceland did not show any significant effect [127], while a study from Israel showed significantly lower hematocrit levels in the summer [128]. A third, large-scale study from the U.K. showed a „slight seasonal trend” [124]. Our results are in accordance with this pattern, as we found a statistically significant, but clinically minor difference between winter and summer values.

Hemoglobin levels were significantly associated with the maximum daily temperature in a study by Hoekstra et al. of 130000 blood donors in the Netherlands [129]. In a recent paper Sebok et al. examined the extent to which environmental temperature contributes to the seasonal trend in deferral rates of presenting donors due to low hematocrit at the American Red Cross Blood Services in a very large population. Hematocrit deferral rates showed a strong seasonal trend with a peak in the summer months and demonstrated a strong association with environmental temperature, which accounted for 77 percent of the variation in hematocrit deferral rates [130]. The area with the highest temperature variability during the year demonstrated the strongest relationship between Htc deferral rate and temperature, which is in concordance with the European results [124,127,129]. Our study showed a statistically significant but weak negative correlation between ambient temperature and hematocrit which is in accordance with these results, as Hungary is located in the continental climate zone characterized by relatively high annual temperature variability. Decrease in hematocrit during the summer might be explained by hemodilution occurring in warm weather due to increased plasma volume [131]. Also, significant hemoconcentration as a response to extreme cold has been described in male Antarctic workers with a mean hematocrit value of 52.5 % at -38 °C

and 48.0 % at 0 °C [132]. These results support the finding that blood and plasma play an important role in thermoregulatory responses [133].

In our study both M0 and M1 indices showed significant differences between summer and winter values. This is in contrast with the results of Fröhlich et al. who found no statistically significant seasonal alteration in red blood cell aggregation. The contrast between results may arise from differences in the study population: Fröhlich et al. studied 16 young (20-41 years old), healthy subjects, while our patients were substantially older and suffering from vascular diseases. Fibrinogen, an important determinant of red blood cell aggregation has been shown to exhibit an age-dependent seasonal rhythm present in the elderly but lacking in young individuals [123,134]. We suspect that seasonal variance in red blood cell aggregability may follow a similar pattern in different age groups. To our knowing this is the first study to show a negative correlation between ambient temperature and red blood cell aggregation. However, the exact mechanism by which outdoor temperature influences the result of red blood cell aggregometry is unknown.

Epinephrine-induced platelet aggregation also showed a seasonal fluctuation in the present investigation. We are unaware of any previous study to show a circannual variation in platelet aggregability in ASA treated vascular patients. Previous studies have shown significant seasonal variation in mean platelet volume and platelet distribution width [33]. Von Willebrand factor has also been proved to show seasonal variation [33,134]; similarly to our results, it peaked in April while it reached its minimum in October. Platelet aggregation induced with 10 µM ADP showed a very weak association with outdoor temperature in our study, but this result is questionable as neither aggregation induced with the smaller dose of ADP nor that induced with collagen and epinephrine showed similar correlations.

Meteorological front activity can be characterized by rapid changes in air pressure. As neither positive nor negative association was found between the examined hemorheological and

platelet aggregation parameters and the extent of changes in air pressure at the time point of sampling, cold or warm fronts do not seem to have an instant effect on these parameters. On the other hand, it needs further examinations whether meteorological fronts have a delayed effect on these variables.

Diet may substantially influence several hemorheological parameters and platelet aggregation [135,136]. Winter-related difficulties in achieving weight loss relative to the summer have been described [137]. Small seasonal fluctuations were observed in body weight and time spent on various physical activities [39], factors that have been shown to be related to hemorheological factors and platelet aggregability [138,139]. It has been shown both cross-sectionally and longitudinally that relatively higher levels of physical activity are associated with lower levels of fibrinogen, CRP, vWF, t-PA and platelet aggregability. Seasonal variations in physical activity may thus contribute to the seasonal variations observed.

Seasonal variation in intake of fat and vitamin C and E was found in a study by Woodhouse et al [40]. Fat intake peaked in the winter while vitamin C and E intakes reached their highest level in summer.

Tseng et al. detected seasonal patterns in monthly hemoglobin A_{1C} values in a large cohort of diabetic patients with higher levels in the winter than in the summer. Regions with colder winter temperatures had larger winter-summer contrasts than did those with warmer winter temperatures [41]. Previous studies of populations and healthy volunteers have demonstrated fluctuations in glucose and insulin sensitivity, with higher levels in the fall or winter in most studies [42,43,44]. Seasonal metabolic alterations, differences in food intake and physical activity may play an important role in the observed seasonal differences of hemorheological parameters and platelet aggregability in our study, however, further investigation is needed to prove this theory.

5.4. Conclusion

Our study showed that certain hemorheological parameters and platelet aggregability exhibited seasonal differences in aspirin treated vascular patients. The observed differences might contribute to the seasonal fluctuation in the mortality of cardiovascular diseases known from the literature. Our results might also be of importance in the case of longitudinal investigations when consecutive samplings take place in different periods of the year. In these cases seasonal alterations may interfere with study results. Our results support the theory that beside seasonal variations in diet and physical activity, annual fluctuation in ambient temperature may contribute to seasonal variation in certain hemorheological parameters. Meteorological front activity do not seem to have an immediate effect on the examined parameters.

6. List of abbreviations

ADP - adenosine-5'-diphosphate

ASA - acetylsalicylic acid

BMI- body mass index

CRP - C-reactive protein

Coll - collagen

Epi - epinephrine

IGT - impaired glucose tolerance

NGT- normal glucose tolerance

NSAID - non-steroid anti-inflammatory drug

OGTT - oral glucose tolerance test

PAI-1 - plasminogen activator inhibitor-1

PPP- platelet poor plasma

PRP- platelet rich plasma

RBC - red blood cell

S.E.M.- standard error of the means

Spont. aggr. - spontaneous aggregation

sP-selectin - soluble P-selectin

t-PA - tissue plasminogen activator

vWF-von Willebrand factor

7. References

- 1 Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. *J Clin Invest* 1987; 80:1527-34.
- 2 Avellone G, Garbo D, Panno AV, Cordova R, alletto G, Raneli G, De Simone R, Strano A, Bompani GD: Hemorheological components in the pre-geriatric and geriatric range in a randomly selected western Sicily population sample (Casteldaccia Study). *Clin Hemorheol* 1993; 13:83-92.
- 3 Ott E, Nidererkorn K, Fazekas F, Korner E, Ossama N, Lechner H. The implication of hemorheologica abnormalities in cerebrovascular diseases. *Clin Hemorheol* 1986; 6:331-6.
- 4 Barasch E, Benderly M, Graff E, Behar S, Reicher-Reiss H, Caspi A, Pelled B, Reisin L, Roguin N, Goldbourt U. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. *J Clin Epidemiol* 1995; 48:757-65.
- 5 Hager K, Felicetti M, Seefried G, Platt D. Fibrinogen and aging. *Aging* 1994; 6:133-8.
- 6 de Simone G, Devereux RB, Chien S, Alderman MH, Atlas SA, Laragh JH. Relation of blood viscosity to demographic and physiologic variables and to cardiovascular risk factors in apparently normal adults. *Circulation* 1990; 81:107-17.
- 7 Sharp DS, Abbott RD, Burchfiel CM, Rodriguez BL, Tracy RP, Yano K, Curb JD. Plasma fibrinogen and coronary heart disease in elderly Japanese-American men. *Arterioscler Thromb Vasc Biol* 1996; 16:262-8.
- 8 Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, Meade TW. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. *Thromb Haemost* 1992; 68:261-3.

9 Yamanishi J, Sano H, Saito K, Furuta Y, Fukuzaki H. Plasma concentrations of platelet-specific proteins in different stages of essential hypertension: interactions between platelet aggregation, blood lipids and age. *Thromb Haemost* 1985; 54:539-43.

10 Chao FC, Tullis JL, Alper CA, Glynn RJ, Silbert JE. Alteration in plasma proteins and platelet functions with aging and cigarette smoking in healthy men. *Thromb Haemost* 1982; 47:259-64.

11 Le Devehat C, Vimeux M, Khodabandehlou T. Blood Rheology in Patients with Diabetes Mellitus. *Clin Hemorheol Microcirc* 2004; 30:297-300.

12 Mellinshoff C, Reininger AJ, Wurzinger LJ, Landgraf R, Hepp KD. Influence of Glycemic Control on Viscosity and Density of Plasma and Whole Blood in Type-1 Diabetic Patients. *Diabetes Res Clin Pract* 1996; 33:75-82.

13 Vekasi J, Marton ZS, Kesmarky G, Cser A, Russai R, Horvath B. Hemorheological Alterations in Patients with Diabetic Retinopathy. *Clin Hemorheol Microcirc* 2001; 24:59-64.

14 Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Roles of the receptor for advanced glycation end products in diabetes-induced vascular injury, *J Pharmacol Sci* 2005; 97:305-11.

15 Brun JF. Hormones, metabolism and body composition as major determinants of blood rheology: potential pathophysiological meaning. *Clin Hemorheol Microcirc* 2002; 26:63-79.

16 Brun JF, Aloulou I, Varlet-Marie E. Hemorheological aspects of the metabolic syndrome: markers of insulin resistance, obesity or hyperinsulinemia? *Clin Hemorheol Microcirc* 2004; 30:203-9.

17 Koltai K, Feher G, Kesmarky G, Keszthelyi ZS, Czopf L, Toth K. The effects of blood glucose levels on hemorheological parameters, platelet aggregation and activation in oral glucose tolerance tests. *Clin Hemorheol Microcirc* 2006; 35:517-25.

- 18 Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. *Diabetes Care* 2003; 26:2181-8.
- 19 Mabley JG, Soriano FG. Role of nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic vascular dysfunction. *Curr Vasc Pharmacol* 2005; 3:247-52.
- 20 Ernst E, Matrai A. Altered red and white blood cell rheology in type II diabetes, *Diabetes* 1986; 35:1412-5.
- 21 Pecsvarady Z, Fischer TC, Darwin CH, Fabok A, Maqueda TS, Saad M, Meiselman HJ. Decreased polymorphonuclear leucocyte deformability in NIDDM. *Diabetes Care* 1994; 17:57-63.
- 22 Caimi G, Lo Presti L, Montana M, Carollo C, Amodeo G, Romano A, Canino B. Polymorphonuclear leukocyte: rheology, metabolism and integrin pattern in vascular atherosclerotic disease and in type 2 diabetes mellitus. *Clin Hemor Microcirc* 2004; 30:229-35.
- 23 Smolensky MH, D'Alonzo GE. Medical chronobiology: concepts and applications. *Am Rev Respir Dis* 1993; 147:2-19.
- 24 Spencer FA, Goldberg RJ. Seasonal distribution of acute myocardial infarction in the National Registry of Myocardial Infarction. *J Am Coll Cardiol* 1998; 31:1226-33.
- 25 Ornato JP, Siegel L, Craren EJ, Nelson N. Increased incidence of cardiac death attributed to acute myocardial infarction during winter. *Coron Artery Dis* 1990; 1:199-203.
- 26 Wolff L, White PD. Acute coronary occlusion. *Boston Med Surg J* 1936; 195:13.
- 27 Kloner RA, Poole WK, Perritt RL. When throughout the year is coronary death most likely to occur? A 12-year population-based analysis of more than 220 000 cases. *Circulation* 1999; 100:1630-4.

- 28 Marshall RJ, Scragg R, Bourke P. An analysis of the seasonal variation of coronary heart disease and respiratory disease mortality in New Zealand. *Int J Epidemiol* 1988; 17:325-31.
- 29 Fröhlich M, Sund M, Thorand B, Hutchinson WL, Pepys MB, Koenig W. Lack of seasonal variation in C-reactive protein. *Clin Chem* 2002; 48:575-7.
- 30 Sayer JW, Wilkinson P, Ranjadayalan K, Ray S, Marchant B, Timmis AD. Attenuation or absence of circadian and seasonal rhythms of acute myocardial infarction. *Heart* 1997; 77:325-9.
- 31 Woodhouse PR, Khaw KT, Plummer M. Seasonal variation of blood pressure and its relationship to ambient temperature in an elderly population. *J Hypertens* 1993; 11:1267-74.
- 32 Brennan PJ, Greenberg G, Miall WE, Thompson SG. Seasonal variation in arterial blood pressure. *Br Med J (Clin Res Ed)* 1982; 285:919-23.
- 33 Maes M, Scharpé S, Cooreman W, Wauters A, Neels H, Verkerk R, De Meyer F, D'Hondt P, Peeters D, Cosyns P. Components of biological, including seasonal, variation in hematological measurements and plasma fibrinogen concentrations in normal humans. *Experientia* 1995; 5:141-9.
- 34 Nicolau GY, Haus E, Plîngă L, Dumitriu L, Lakatua D, Popescu M, Ungureanu E, Sackett-Lundeen L, Petrescu E. Chronobiology of pituitary-thyroid functions. *Rom J Endocrinol* 1992; 30:125-48.
- 35 Nicolau GY, Haus E, Popescu M, Sackett-Lundeen L, Petrescu E. Circadian, weekly, and seasonal variations in cardiac mortality, blood pressure, and catecholamine excretion. *Chronobiol Int* 1991; 8:149-59.
- 36 Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. *Lancet* 1994; 343:435-9.

- 37 Mavri A, Guzic-Salobir B, Salobir-Pajnic B, Keber I, Stare J, Stegnar M. Seasonal variation of some metabolic and hemostatic risk factors in subjects with and without coronary artery disease. *Blood Coagul Fibrinolysis* 2001; 12: 359–65.
- 38 Fröhlich M, Sund M, Russ S, Hoffmeister A, Fischer HG, Hombach V, Koenig W. Seasonal variations of rheological and hemostatic parameters and acute-phase reactants in young, healthy subjects. *Arterioscler Thromb Vasc Biol* 1997; 17:2692-7.
- 39 Van Staveren WA, Deurenberg P, Burema J, De Groot LC, Hautvast JG. Seasonal variation in food intake, pattern of physical activity and change in body weight in a group of young adult Dutch women consuming self-selected diets. *Int J Obes* 1986; 10:133-45.
- 40 Woodhouse PR, Khaw KT. Seasonal variation of risk factors for cardiovascular disease and diet in older adults. *Int J Circumpolar Health* 2000; 59:204-9.
- 41 Tseng CL, Brimacombe M, Xie M, Rajan M, Wang H, Kolassa J, Crystal S, Chen TC, Pogach L, Safford M. Seasonal patterns in monthly hemoglobin A1c values. *Am J Epidemiol* 2005; 161:565-74.
- 42 Jarrett RJ, Murrells TJ, Shipley MJ, Hall T. Screening blood glucose values: effects of season and time of day. *Diabetologia* 1984; 27:574-7.
- 43 Suarez L, Barrett-Connor E. Seasonal variation in fasting plasma glucose levels in man. *Diabetologia* 1982; 22:250-3.
- 44 Gravholt CH, Holck P, Nyholm B, Christiansen E, Erlandsen M, Schmitz O. No seasonal variation of insulin sensitivity and glucose effectiveness in men. *Metabolism* 2000; 49:32-8.
- 45 Iseki K, Morita O, Fukiyama K. Seasonal variation in the incidence of end-stage renal disease. *Am J Nephrol* 1996; 16:375-81.

46 Widlansky ME, Vita JA, Keyes MJ, Larson MG, Hamburg NM, Levy D, Mitchell GF, Osypiuk EW, Vasan RS, Benjamin EJ. Relation of season and temperature to endothelium-dependent flow-mediated vasodilation in subjects without clinical evidence of cardiovascular disease (from the Framingham Heart Study). *Am J Cardiol* 2007; 100:518-23.

47 Klein-Weigel P, Krall K, Falkensammer J, Heinz-Erian P, Ulmer H, Fraedrich G. Lack of seasonal variation in flow-mediated dilatation of the brachial artery in women with primary Raynaud's phenomenon and healthy controls. *Vasa* 2003; 32:69-73.

48 Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. *Eur Heart J* 2006; 27:107-13.

49 Józsan P. New trends in mortality and life expectancy: epidemiologic transition in Hungary? *Orv Hetil* 2003; 144:451-60.

50 Tóth K, Késmárky G. Kardiológiai betegségek. In: A klinikai hemorheologia alapjai. Eds.: Bernát-Pongrácz, Kornétás, 1999; 95-114.

51 Keatinge WR, Donaldson GC, Bucher K, Jendritzky G, Cordioli E, Martinelli M, Katsouyanni K, Kunst AE, McDonald C, Näyhä S, Vuori I; Eurowinter Group. Cold exposure and winter mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes in warm and cold regions of Europe. *Lancet* 1997; 349:1341-6.

52 Keatinge WR, Donaldson GC, Bucher K, Jendritzky G, Cordioli E, Martinelli M, Katsouyanni K, Kunst AE, McDonald C, Näyhä S, Vuori I; Eurowinter Group. Winter mortality in relation to climate. *Int J Circumpolar Health* 2000; 59:154-9.

53 Seretakakis D, Lagiou P, Lipworth L, Signorello LB, Rothman KJ, Trichopoulos D. Changing seasonality of mortality from coronary heart disease. *JAMA* 1997; 278:1012-4.

54 Crawford VL, McNerlan SE, Stout RW. Seasonal changes in platelets, fibrinogen and factor VII in elderly people. *Age Ageing* 2003; 32:661-5.

- 55 Lloyd EL. The role of cold in ischaemic heart disease: a review. *Public Health* 1991; 105:205-15.
- 56 Crawford VL, McCann M, Stout RW. Changes in seasonal deaths from myocardial infarction. *QJM* 2003; 96:45-52.
- 57 Baskurt OK, Levi R, Caglayan S, Dikmenoglu N, Ucer O, Guner R, Yorukan S. The role of hemorheologic factors in the coronary circulation. *Clin Hemorheol* 1991; 11:121-7.
- 58 Carter C, McGee D, Reed D, Yano K, Stemmermann G. Hematocrit and the risk of coronary heart disease: The Honolulu Heart Program. *Am Heart J* 1983; 105:674-9.
- 59 Dormandy J. Cardiovascular diseases, in: *Clinical Hemorheology*, Chien S, Dormandy J, Ernst E, Matrai A, eds. Martinus Nijhoff Publishers, Dordrecht, 1987, 165-94.
- 60 Junker R, Heinrich J, Ulbrich H, Schulte H, Schönfeld R, Köhler E, Assmann G. Relationship between plasma viscosity and the severity of coronary heart disease. *Arterioscler Thromb Vasc Biol* 1998; 18:870-5.
- 61 Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham Study. *Am Heart J* 1987; 113:1006-10.
- 62 Kesmarky G, Toth K, Habon L, Vajda G, Juricskay I. Hemorheological parameters in coronary artery disease. *Clin Hemorheol Microcirc* 1998; 18:245-51.
- 63 Neumann FJ, Katus HA, Hoberg E, Roebruck P, Braun M, Haupt HM, Tillmanns H, Kubler W. Increased plasma viscosity and erythrocyte aggregation-indicators of an unfavourable clinical outcome in patients with unstable angina pectoris. *Br Heart J* 1991; 66:425-30.
- 64 Neumann FJ, Tillmanns H, Roebruck P, Zimmermann R, Maupt HM, Kubler W. Haemorrheological abnormalities in unstable angina pectoris: a relation independent of risk factor profile and angiographic severity. *Br Heart J* 1989; 62:421-8.

- 65 Kenyeres P, Juricskay I, Tarsoly P, Kesmarky G, Mühl D, Toth K, Bogar L. Low hematocrit per blood viscosity ratio as a mortality risk factor in coronary heart disease. *Clin Hemorheol Microcirc* 2008; 38:51-6.
- 66 Toth K, Kesmarky G, Alexy T. Clinical significance of hemorheological alterations. Eds.: Baskurt OK, Hardeman MR, Rampling MW, Meiselman HJ, IOS Press, 2007; 392-432.
- 67 Toth K, Bogar L, Juricskay I, Keltai M, Yusuf S, Haywood LJ, Meiselman HJ. The effect of RheothRx Injection on the hemorheological parameters in patients with acute myocardial infarction. *Clin Hemorheol Microcirc* 1997; 17:117-25.
- 68 Toth K. Connection between classical risk factors and hemorheological parameters in ischemic heart disease. *Turk J Hemat* 2000; 17:209-11.
- 69 Tooke JA and Shore AC. The regulation of microvascular function in diabetes mellitus, in: *Chronic complications of Diabetes*, Pickup JC and Williams G, eds. Blackwell, Boston, 1994, 34-41.
- 70 Babu N, Singh M. Influence of hyperglycemia on aggregation, deformability and shape parameters of erythrocytes. *Clin Hemorheol Microcirc* 2004; 31:273-80.
- 71 Le Devehat C, Khodabandehlou T, Vimeux M and Aouane F. Diabetes mellitus: its effects on blood rheological properties and microcirculatory consequences. *Clin Hemorheol* 1996; 16:677-83.
- 72 Ziegler O, Guerci B, Candiloros H, Méjean L, Donner M, Stoltz JF, Drouin P. Increased erythrocyte aggregation in insulin-dependent diabetes mellitus and its relationship to plasma factors: A multivariate analysis. *Metabolism* 1994; 43:1182-6.
- 73 Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. *Thromb Res* 1998; 90:181-90.

74 Véricel E, Januel C, Carreras M, Moulin P, Lagarde M. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. *Diabetes* 2004; 53:1046-51.

75 Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. *Thromb Res* 2004; 113:101-13.

76 De La Cruz JP, Arrebola MM, Villalobos MA, Pinacho A, Guerrero A, González-Correa JA, de la Cuesta FS. Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and platelet-subendothelium interaction. *Eur J Pharmacol* 2004; 484:19-27.

77 Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. *Am J Cardiol* 2003; 92:1362-5.

78 André P, Hartwell D, Hrachovinová I, Saffaripour S, Wagner D. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. *Proc Natl Acad Sci USA* 2000; 25:13835-40.

79 Blann D, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. *Eur Heart J* 2003; 24:2166-79.

80 Conway SGD, Pearce LA, Chin BSP, Hart RG, Lip GYH. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation. *Circulation* 2002; 106:1962-7.

81 Klose HJ, Volger E, Brechtelsbauer H, Heinrich L, Schmied-Schonbein H. Microrheology and light transmission in blood. *Pflugers Arch* 1972; 333:126-39.

82 Marton ZS, Kesmarky G, Vekasi J, Cser A, Russai R, Horvath B and Toth K. Red blood cell aggregation measurements in whole blood and in fibrinogen solutions by different methods. *Clin Hemorheol Microcirc* 2001; 24:75-83.

- 83 Khodabandehlou T, Zhao H, Vimeux M, Aouane F, Le Devehat C. Hemorheological consequences of hyperglycaemic spike in healthy volunteers and insulin-dependent diabetics. *Clin Hemorheol Microcirc* 1998; 19:105-14.
- 84 Samocha-Bonet D, Lichtenberg D, Tomer A, Deutsch V, Mardi T, Goldin Y, Abu-Abeid S, Shenkerman G, Patshornik H, Shapira I, Berliner S. Enhanced erythrocyte adhesiveness/aggregation in obesity corresponds to low-grade inflammation. *Obes Res* 2003; 11:403-7.
- 85 Bo M, Raspo S, Morra F, Cassader M, Isaia G, Poli L. Body fat is the main predictor of fibrinogen levels in healthy non-obese men. *Metabolism* 2004; 53:984-8.
- 86 Pérez-Martin A, Dumortier M, Pierrisnard E, Raynaud E, Mercier J, Brun JF. Multivariate analysis of relationships between insulin sensitivity and blood rheology: Is plasma viscosity a marker of insulin resistance? *Clin Hemorheol Microcirc* 2001; 25:91-103.
- 87 Lo Presti R, Sinagra D, Montana M, Scarpitta AM, Catania A, Caimi G. Haemorheological profile in metabolic syndrome. *Clin Hemorheol Microcirc* 2002; 26: 241-47.
- 88 Opper C, Weiner N, Xu F, Adam W, Fruhstorfer H, Wesemann W. Daily variations of functional parameters and density distribution in human blood platelets. *Chronobiol Int* 1994; 11:309-19.
- 89 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002; 324:71-86.
- 90 Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. *J Am Coll Cardiol* 2005; 45:1157-64.
- 91 Spada RS, Toscano G, Chiarenza S. Ischemic stroke and fibrinogen in the elderly. *Arch Gerontol Geriatr Suppl* 2004; 9:403-6.

- 92 Tofler GH, Massaro J, Lavy D, Mittleman M, Sutherland P, Lipinska I, et al. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). *Am J Cardiol* 2005; 96:1280-2.
- 93 Yamashita T, Sato A, Ikarugi H, Inoue A, Kitamori K, Ishii H, et al. Significantly reduced spontaneous thrombolytic activity in older men: a possible explanation for the gender differences in risk. *Thromb Res* 2005; 116:127-31.
- 94 Ranby M, Bergsdorf N, Nilsson T, Winblad B, Bucht A. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. *Clin Chem* 1986; 32:2160-5.
- 95 Bastyr III EJ, Kadrofske MM, Vinik AI. Platelet activity and phosphoinositide turnover increase with advancing age. *Am J Med* 1990; 88:601-6.
- 96 Gleerup G, Winther K. The effect of ageing on human platelet sensitivity to serotonin. *Eur J Clin Invest* 1988; 18:504-6.
- 97 Vallejo G, Escudero J.R.. An examination of the robustness of the modified Brown-Forsythe and Welch-James tests in the multivariate split-plot designs. *Psicothema* 2000; 12: 701-11.
- 98 Macchi L, Christianens L, Brabant S, Sorel N, Allal J, Mauco G, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. *Thromb Res* 2002; 107:45-9.
- 99 Hankey GJ, Eikelboom JW. Aspirin resistance. *Lancet* 2006; 367:606-17.
- 100 Gum PA, Kottke-Marchant K, Poggio ED, Gum H, Welsh PA, Brooks LM, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. *Am J Cardiol* 2001; 88:230-5.
- 101 Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. *Stroke* 2000; 31:591-5.

102 Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. *Circulation* 2003; 108:542-7.

103 Marton Z, Horvath B, Alexy T, Kesmarky G, Gyevnar Z, Czopf L, Habon T, Kovacs L, Papp E, Mezey B, Roth E, Juricskay I, Toth K. Follow-up of hemorheological parameters and platelet aggregation in patients with acute coronary syndromes. *Clin Hemorheol Microcirc* 2003; 29:81-94.

104 Gum PA, Kottke-Marchant K, Welsh PA, Brooks L, Sapp SK, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol* 2003; 41:961-5.

105 Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. *J Neurol* 2003; 250:63-6.

106 Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. *Catheter Cardiovasc Interv* 2003; 59:295-302.

107 Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. *Thromb Haemost* 2003; 89:783-7.

108 Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. *J Am Coll Cardiol* 2004; 43:979-84.

109 Portnay EL, Foody JM, Rathore SS, Wang Y, Masoudi FA, Curtis JP, et al. Prior aspirin use and outcome in elderly patients hospitalized with acute myocardial infarction. *J Am Coll Cardiol* 2003; 41:961-5.

- 110 Lee PY, Chen WH, Ng W, Cheng X, Kwok JYY, Tse HF, Lau CP. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. *Am J Med* 2005;116:723-7.
- 111 Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, et al. The origins of age-related proinflammatory state. *Blood* 2005; 105:2294-9.
- 112 Otsuka M, Hayashi Y, Ueda H, Imazu M, Kohno N. Predictive value of preprocedural fibrinogen concerning coronary stenting. *Atherosclerosis* 2002; 164:371-8.
- 113 Folsom AR, Wu KK, Rasmussen M, Chambless LE, Aleksic N, Nieto FJ. Determinants of population changes in fibrinogen and factor VII over 6 years: The atherosclerosis risk in communities (ARIC) study. *Arterioscler Thromb Vasc Biol* 2000; 20:601-6.
- 114 de Maat MP, Arnold AE, van Buuren S, Wilson JH, Kluft C. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. *Thromb Haemost* 1996; 76:166-70.
- 115 Sane DC, McKee SA, Malinin A, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. *Am J Cardiol* 2002; 90:893-5.
- 116 Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, et al: Aspirin response and failure in cerebral infarction. *Stroke* 1993; 24:345-50.
- 117 Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. *Stroke* 1994; 25:2331-6.
- 118 Késmárky G, Horváth B, Tóth K. Haemorheologiai tényezők. In: *Atherosclerosis*, Ed.: Császár A, Synergo, 2004; 136-41.

- 119 Bogar L, Juricskay I, Kesmarky G, Feher G, Kenyeres P, Toth K. Gender differences in hemorheological parameters of coronary artery disease patients. *Clin Hemorheol Microcirc* 2006; 35:99-103.
- 120 Crawford VL, Sweeney O, Coyle PV, Halliday IM, Stout RW. The relationship between elevated fibrinogen and markers of infection: a comparison of seasonal cycles. *QJM* 2000; 93:745-50.
- 121 Stout RW, Crawford V. Seasonal variations in fibrinogen concentrations among elderly people. *Lancet* 1991; 338:9-13.
- 122 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. *Ann Intern Med* 1993; 118:956-63.
- 123 Stout RW, Crawford VL, McDermott MJ, Rocks MJ, Morris TC. Seasonal changes in haemostatic factors in young and elderly subjects. *Age Ageing* 1996; 25:256-8.
- 124 Sanders C. Some erythrocyte parameters on a cross section of U.K.A.E.A. employees. *Lab Pract* 1965; 14:1390-6.
- 125 Otto C, Donner MG, Schwandt P, Richter WO. Seasonal variations of hemorheological and lipid parameters in middle-aged healthy subjects. *Clin Chim Acta* 1996; 256:87-94.
- 126 Cinar Y, Senyol AM, Duman K. Blood viscosity and blood pressure: role of temperature and hyperglycemia. *Am J Hypertens* 2001; 14:433-8.
- 127 Björnsson OJ, Davidsson D, Filippusson H, Olafsson O, Sigfússon N, Thorsteinsson T. Distribution of haematological, serum and urine values in a general population of middle-aged men. The Reykjavik Study. *Scand J Soc Med Suppl* 1984; 32:1-12.
- 128 Kristal-Boneh E, Froom P, Harari G, Shapiro Y, Green MS. Seasonal changes in red blood cell parameters. *Br J Haematol* 1993; 85:603-7.

- 129 Hoekstra T, Veldhuizen I, van Noord PA, de Kort WL. Seasonal influences on hemoglobin levels and deferral rates in whole-blood and plasma donors. *Transfusion*. 2007; 47:890-4.
- 130 Sebok MA, Notari EP, Chambers LA, Benjamin RJ, Eder AF. Seasonal temperature variation and the rate of donor deferral for low hematocrit in the American Red Cross. *Transfusion* 2007; 47:890-4.
- 131 Morimoto T, Shiraki K, Inoue T, Yoshimura H. Seasonal variation of water and electrolyte in serum with respect to homeostasis. *Jpn J Physiol* 1969; 19:801-13.
- 132 Boiko ER, Bashkanov AS, Maklakova GN, Pitolitsyna NN.[Peripheral blood parameters in humans under low temperature conditions in the far North] *Fiziol Cheloveka* 2001; 27:140-1.
- 133 van Beaumont W, Underkofler S, van Beaumont S. Erythrocyte volume, plasma volume, and acid-base changes in exercise and heat dehydration. *J Appl Physiol* 1981; 50:1255-62.
- 134 Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. *Circulation* 2007; 115:996-1003.
- 135 Aslam R, Saeed SA, Ahmed S, Connor JD. Lipoproteins inhibit platelet aggregation and arachidonic acid metabolism in experimental hypercholesterolaemia. *Clin Exp Pharmacol Physiol* 2008; 35:656-62.
- 136 Din JN, Harding SA, Valerio CJ, Sarma J, Lyall K, Riemersma RA, Newby DE, Flapan AD. Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. *Atherosclerosis* 2008; 197:290-6.
- 137 Zahorska-Markiewicz B. Weight reduction and seasonal variation. *Int J Obes* 1980; 4:139-43.

138 Antonopoulou S, Fragopoulou E, Karantonis HC, Mitsou E, Sitara M, Rementzis J, Mourelatos A, Ginis A, Phenekos C Effect of traditional Greek Mediterranean meals on platelet aggregation in normal subjects and in patients with type 2 diabetes mellitus. *J Med Food* 2006; 9:356-62.

139 Solá E, Vayá A, Contreras T, Falcó C, Corella D, Hernández A, Aznar J. Rheological profile in severe and morbid obesity. Preliminary results. *Clin Hemorheol Microcirc* 2004; 30:415-8.

8. Publications of the author

1. Szapary L, Horvath B, Marton ZS, Alexy T, Kesmarky G, Szots M, Koltai K, Czopf J, Toth K. Short term effect of low dose atorvastatin on hemorheological parameters, platelet aggregation and endothelial function in cerebrovascular patients with dyslipidemia. *CNS Drugs* 2004; 18:165-72. (IF: 4.180)
2. Horváth B, Hegedüs D, Szapáry L, Márton ZS, Alexy T, Koltai K, Gyevnár ZS, Juricskay I, Tóth K, Késmárky G. A von Willebrand faktornak, mint az endothelium diszfunkció markerének vizsgálata érbetegekben. *Orv Hetil* 2003; 50:2471-6.
3. Alexy T, Stef Gy, Márton Zs, Horváth B, Koltai K, Pálfi A, Fehér G, Bócsa Z, Pusch G, Szapáry L, Késmárky G, Veress G, Tóth K. A rutinszerűen alkalmazott trombocita aggregáció gátló kezelés hatékonyságának felmérése érbetegekben. *Kardiológus* 2003; 2:5-24.
4. Szapáry L, Horváth B, Márton Zs, Alexy T, Késmárky G, Szóts M, Pusch G, Gaál V, Pálfi A, Koltai K, Juricskay I, Tóth K. A krónikus ischaemiás agyérbetegségek haemorheologiai jellemzői. *Agyérbetegségek* 2003; 9:2-7.
5. Marton ZS, Halmosi R, Alexy T, Horvath B, Toth A, Feher G, Koltai K, Kesmarky G, Habon T, Sumegi B, Hideg K, Toth K. Hemorheological methods in drug research. *Clin Hemorheol Microcirc* 2004; 30:243-52. (IF: 0.630)
6. Alexy T, Toth A, Marton ZS, Horvath B, Koltai K, Feher G, Kesmarky G, Kalai T, Hideg K, Sumegi B, Toth K. Inhibition of ADP-evoked platelet aggregation by selected poly(ADP-ribose) polymerase inhibitors. *J Cardiovasc Pharmacol* 2004; 43:423-31. (IF: 1.576)
7. Keszthelyi Zs, Past T, Koltai K, Szabó L, Mózsik Gy. A króm(III)ion fokozza a glukóz hasznosulását 2-es típusú diabetes mellitusban. *Orv Hetil* 2003; 144:2073-6.
8. Szapáry L, Szóts M, Horváth B, Márton Zs, Alexy T, Késmárky G, Juricskay I, Nagy F, Gaál V, Pálfi A, Koltai K, Tóth K. A kardiovaszkuláris rizikófaktorok hatása az agyérbetegek haemorheologiai viszonyaira. *Orv Hetil* 2003; 144:1085-90.

9. Keszthelyi Zs, Past T, Koltai K, Szabó L, Mózsik Gy. Króm-és szelénionok szerepe a glükóz-felhasználás sebességének szabályozásában. *Metabolizmus* 2004; 2:97-103.
10. Keszthelyi Z, Past T, Lukats B, Koltai K, Karadi Z. The central effect of chromium on glucose metabolism. *Pharmacopsychiatry* 2004; 37:242. (IF: 2.089)
11. Deres P, Koltai K, Keszthelyi Zs, Tóth K. Speciális szempontok a metabolikusan érintett iszkémiás szívbetegségek kezelésében. *Háziorv Továbbk Szle* 2003; 8:503-7.
12. Szapary L, Csalódi R, Pusch G, Horváth B, Alexy T, Márton Zs, Késmárky G, Szóts M, Koltai K, Tóth K. A thrombocytá aggregáció-gátló kezelés hatékonyságának aggregometriás vizsgálata ischaemiás agyérbetegeknél. *Agyérbetegségek* 2003; 9:12-7.
13. Horvath B, Hegedus D, Szapary L, Marton Zs, Alexy T, Koltai K, Czopf L, Wittmann I, Juricskay I, Toth K, Kesmarky G. Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases. *Exp Clin Cardiol* 2004; 9:1-4.
14. Tóth K, Koltai K. Metabolikus szindróma és szívbetegség. *Háziorv Továbbk Szle* 2004; 9:402-6.
15. Feher G, Koltai K, Kesmarky G, Szapary L, Juricskay I, Toth K. Hemorheological parameters and aging. *Clin Hemorheol Microcirc* 2006; 35:89-98. (IF: 1.242)
16. Kesmarky G, Feher G, Koltai K, Horvath B, Toth K. Viscosity, hemostasis and inflammation in atherosclerotic heart diseases. *Clin Hemorheol Microcirc* 2006; 35:67-73. (IF: 1.242)
17. Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P, Kesmarky G, Czopf L, Toth K. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. *Drugs Aging* 2006; 23:559-67. (IF: 2.200)
18. Koltai K, Feher G, Kesmarky G, Keszthelyi Z, Czopf L, Toth K. The effect of blood glucose levels on hemorheological parameters, platelet activation and aggregation in oral glucose tolerance tests. *Clin Hemorheol Microcirc* 2006; 35:517-25. (IF: 1.242)
19. Feher G, Koltai K, Alkonyi B, Papp E, Keszthelyi Z, Kesmarky G, Toth K. Clopidogrel resistance: Role of body mass and concomitant medications. *Int J Cardiol* 2007; 120:188-92. (IF: 2.234)

20. Feher G, Koltai K, Toth K. Are hemorheological parameters independent of aging? Clin Hemorheol Microcirc 2007; 36:181-2. (IF: 1.242)
21. Fehér G, Bagoly E, Kövér F, Koltai K, Hantó K, Pozsgai E, Komoly S, Dóczy T, Tóth K, Szapáry L. The effect of carotid stenting on rheological parameters, free radical production and platelet aggregation. Orv Hetil 2007; 148:2365-70.
22. Feher G, Koltai K, Kesmarky G, Toth K. Hemorheological background of acetylsalicylic acid resistance. Clin Hemorheol Microcirc 2008; 38:143-52. (IF: 1.242)
23. Vekasi J, Koltai K, Gaal V, Toth A, Juricskay I, Kesmarky G. The effect of aspirin on hemorheological parameters of patients with diabetic retinopathy. Clin Hemorheol Microcirc 2008; 39:385-9. (IF: 1.242)
24. Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, Feher G, Horvath OP, Ember I, Kiss I. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res 2008; 28:1917-22. (IF: 1.479)
25. Koltai K, Feher G, Kenyeres P, Lenart I, Alexy T, Horvath B, Marton Zs, Kesmarky G, Toth K. Relation of platelet aggregation and fibrinogen levels to advancing age in aspirin- and thienopyridine-treated patients. Clin Hemorheol Microcirc (in press). (IF: 1.242)
26. Koltai K, Fulop A, Feher G, Kenyeres P, Halmosi R, Tibold A, Czopf L, Kesmarky G, Toth K. Investigation of seasonal differences in hemorheological parameters and platelet aggregability and their association with meteorological factors. Chronobiol Int (under publication).

ACKNOWLEDGEMENTS

These studies were carried out at the Hemorheological Laboratory of the 1st Department of Medicine, Medical School of the University of Pécs in 2002-2005.

First of all I would like to express my thanks to my teacher and project leader, Prof. Dr. Kálmán Tóth for his support and encouraging words at critical points of my work that were decisive for me to carry on my studies.

I thank Dr. Gábor Késmárky, leader of the Hemorheological Laboratory for being a thorough advisor and lecturer.

I also thank for the previous and present PhD students of the Hemorheological Laboratory, Dr. Zsolt Márton, Dr. Beáta Horváth, Dr. Tamás Alexy, Dr. Gergely Fehér and Dr. Péter Kenyeres for their contribution in executing my investigations.

I am grateful to Dr. László Czopf, Dr. István Juricskay, Dr. Róbert Halmosi and Prof. Dr. István Wittman for inspiring my investigations with great ideas.

I would like to express my gratitude to Dr. Judit Vékási and Dr. Zsuzsanna Keszthelyi for their help in recruiting patients to my studies.

I want to express my thanks to the technicians of the Hemorheological Laboratory, Mrs. Kornélia Fazekas Tapasztó and Mrs. László Nagy for their reliable work.

I thank Antal Tibold for being my best companion in work as well.

At last, I dedicate my work to my parents who with their caring love gave me the freedom to do what I am interested in.